A case of amyotrophic lateral sclerosis/frontotemporal lobar degeneration with apraxia of eyelid opening

Clinical Neurology

Volumn 50, Issue 9, 2010, Pages 645-650

  Yajima, Ryuji ^a   Kasuga, Kensaku ^a   Sato, Tomoe ^a   Ikeuchi, Takeshi ^a   Nishizawa, Masatoyo ^a  

^a NIIGATA UNIVERSITY   (Japan)

Author keywords

Amyotrophic lateral sclerosis; Apraxia of eyelid opening; Frontotemporal lobar degeneration; Progressive non fluent aphasia; Selective serotonin reuptake inhibitor

Indexed keywords

CYSTEINE ETHYL ESTER TC 99M; FLUVOXAMINE MALEATE; SEROTONIN RECEPTOR;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; APHASIA; APRAXIA; ARTICLE; BICEPS BRACHII MUSCLE; BRAIN ATROPHY; BRAIN PERFUSION; BRAIN SCINTISCANNING; CASE REPORT; ELECTROMYOGRAPHY; EYELID DISEASE; EYELID OPENIG APRAXIA; FRONTOTEMPORAL DEMENTIA; HUMAN; LEUKOARAIOSIS; MALE; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; SEROTONINERGIC SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEREOTYPY; TONGUE;

EID: 78049335960     PISSN: 0009918X     EISSN: None     Source Type: Journal    
DOI: 10.5692/clinicalneurol.50.645     Document Type: Article

References (29)

1. Cairns NJ, Bigio EH, Mackenzie IR, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the consortium for frontotemporal lobar degeneration. Acta Neuropathol 2007;114:5-22.
2. Geser F, Martinez-Lage M, Kwong LK, et al. Amyotrophic lateral sclerosis, frontotemporal dementia and beyond: the TDP43 diseases. J Neurol 2009;256:1205-1214.
3. Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006;314:130-133.
4. Arai T, Hasegawa M, Akiyama H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 2006;351:602-611. (Pubitemid 44708852)
5. Mackenzie IR, Neumann M, Bigio EH, et al. Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol 2009;117:15-18.
6. Brooks BR. El Escorial world federation of neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on motor neuron diseases/amyotrophic lateral sclerosis of the world federation of neurology research group on neuromuscular diseases and the El Escorial "clinical limits of amyotrophic lateral sclerosis" workshop contributors. J Neurol Sci 1994;124 Suppl:96-107.
7. Mitsuyama Y, Takamiya S. Presenile dementia with motor neuron disease in Japan. A new entity? Arch Neurol 1979;36:592-593.
8. Mitsuyama Y. Presenile dementia with motor neuron disease in Japan: clinico-pathological review of 26 cases. J Neurol Neurosurg Psychiatry 1984;47:953-959.
9. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration. A consensus on clinical diagnostic criteria. Neurology 1998;51:1546-1554.
10. The Lund and Manchester Groups Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry 1994;57:416-418.
11. Bak TH, O'Donovan DG, Xuereb JH, et al. Selective impairment of verb processing associated with pathological changes in Brodmann areas 44 and 45 in the motor neurone disease-dementia-aphasia syndrome. Brain 2001;124:103-120.
12. Restivo DA, Bianconi C, Ravenni R, et al. ALS and myasthenia: an unusual association in a patient treated with riluzole. Muscle Nerve 2000;23:294-295. (Pubitemid 30064958)
13. Pinto S, de Carvalho M. Amyotrophic lateral sclerosis patients and ocular ptosis. Clin Neurol Neurosurg 2008;110:168-170.
14. Abe K, Fujimura H, Tatsumi C, et al. Eyelid "apraxia" in patients with motor neuron disease. J Neurol Neurosurg Psychiatry 1995;59:629-632.
15. Ikeda M, Shigenobu K, Fukuhara R, et al. Efficacy of fluvoxamine as a treatment for behavioral symptoms in frontotemporal lobar degeneration patients Dement Geriatr Cogn Disord 2004;17:117-121.
16. Moretti R, Torre P, Antonello RM, et al. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur Neurol 2003;49:13-19.
17. Procter AW, Qurne M, Francis PT. Neurochemical features of frontotemporal dementia. Dement Geriatr Cogn Disord 1999;10(Suppl 1):80-84.
18. Franceschi M, Anchisi D, Pelati O, et al. Glucose metabolism and serotonin receptors in the frontotemporal lobe degeneration. Ann Neurol 2005;57:216-225.